A clinic-based sample of 120 adults with type 2 diabetes was evaluated for sleep and anxiety between 30/09/2024 and 30/12/2024. The cohort's mean age was 65.4 years (±9.32). Women comprised 66.7% of participants. The study team recruited patients by random selection in the clinical neurophysiology and internal medicine departments of a single tertiary center in Morocco. The investigators reported demographic data and clinical measures, including HbA1c, as part of the baseline assessment.
Patterns in the data were notable. A large majority—84.2%—met the operational threshold for poor sleep quality on the instrument used. That proportion reflects a high burden of sleep disturbance among the sampled patients. The source did not provide longitudinal follow-up or intervention data.
The authors used the Pittsburgh Sleep Quality Index (PSQI) to quantify sleep quality and the Generalized Anxiety Disorder Scale (GAD-7) to screen for anxiety symptoms. Glycemic control was represented by HbA1c values, although the abstract does not list mean HbA1c or distribution categories. The statistical plan included descriptive analyses, independent two-sample t-tests, chi-square tests, and binary logistic regression. All analyses were performed using Jamovi version 2.6.2. The source lists the instruments and statistical methods but does not provide detailed model coefficients or full variable lists in the abstract.
Mean PSQI score for the sample was 9.18 (±3.73). The mean GAD-7 score was 8.0 (±6.11). Both group-level means suggest clinically relevant sleep complaints and a range of anxiety symptoms across the cohort. Given the PSQI threshold conventions, the authors classified 84.2% of participants as having poor sleep quality. The study abstract does not provide stratified PSQI or GAD-7 distributions by sex, age bands, diabetes duration, or comorbidity burden.
Researchers conducted a binary logistic regression to identify variables associated with poor sleep quality. The model reportedly found no significant relationship between poor sleep and elevated HbA1c. Rather, two variables emerged as statistically significant predictors: older age and higher GAD-7 scores. The investigators therefore observed that anxiety symptom burden and advancing age were independently associated with poor sleep in this cross-sectional sample. The abstract does not supply odds ratios, confidence intervals, p-values, or the full list of covariates entered into the regression model; those details would be in the full text.
These analytic results indicate a stronger cross-sectional link between psychological distress and sleep complaints than between sleep complaints and contemporaneous glycemic control measured by HbA1c. Causality cannot be inferred from this design.
The authors interpreted the findings as evidence that psychological factors—chiefly anxiety—play a substantial role in sleep disturbance among patients with type 2 diabetes. For clinicians, the data suggest that routine assessment of sleep quality and anxiety symptoms may be warranted in outpatient diabetes care. Interventions targeting anxiety or sleep hygiene could be considered as adjuncts to biomedical management, though the study did not evaluate treatment effects. The abstract emphasizes a comprehensive approach that includes psychological and behavioral dimensions alongside standard metabolic care.
The report does not indicate whether specific subgroups (for example, patients with longer diabetes duration, insulin therapy, or other comorbidities) showed different patterns. That lack of subgroup detail limits immediate operationalization into tailored management pathways.
The source reports a cross-sectional observational design conducted over a three-month window at a single center; therefore directionality and causation cannot be established. The abstract does not present regression coefficients, confidence intervals, or exact HbA1c metrics, so the magnitude of the null association with glycemic control cannot be independently assessed here. The study did not report longitudinal outcomes, response to interventions for sleep or anxiety, or mechanistic biomarkers. External validity is uncertain because recruitment occurred in one Moroccan hospital and the sample demographics skewed older and female. Future work should report full model statistics, include longitudinal designs to assess temporal relationships between sleep, anxiety, and glycemic control, and evaluate whether treating anxiety or sleep disturbance improves metabolic outcomes.
The investigators reported their main findings and methods in the abstract; however, additional methodological specifics and complete statistical output are available only in the full manuscript, which the abstract references but does not reproduce.